James Strachan

Is autologous cell therapy a realistic proposition for solid tumors?

The question that’s on everyone’s lips: how can developers tackle solid tumors and bring cell therapy to millions?

Epigenetic switches are being used to identify the optimal combination of transcription factors required to derive clinically valuable cell types.

We sit down to interview Peter Marks, Director of the Center for Biologics Evaluation and Research at the US FDA.

Find out how a random act of kindness set Antoinette Gawin on the path to becoming a VP in her twenties.

Steve Bates gives us the inside scoop on the UK’s Vaccine Taskforce.

History was made this past month as China's National Medical Products Administration approved the country's first CAR T-cell therapy: Yescarta.

Care must be taken to ensure patients understand the difference between gene therapy and the different kinds of gene editing.

Experts from the BIA got together to discuss how the UK’s biotechnology industry can plug the UK’s worrying skills gap.

What was described by a University of California professor as gene therapy's "single most remarkable achievement?"